ideal treatment duration of tyrosine kinase inhibitors in egfr-mutant nsclc
Published 7 months ago • 120 plays • Length 4:12Download video MP4
Download video MP3
Similar videos
-
6:15
the clinical use of tyrosine kinase inhibitors in egfr-mutant nsclc
-
4:09
tyrosine kinase inhibitors in egfr-mutant nsclc: when and who?
-
0:52
selecting egfr tyrosine kinase inhibitors for egfr-mutant lung cancer
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
4:37
advances in efgr-mutant nsclc treatment
-
2:27
combining egfr and vegf inhibitors for nsclc
-
0:34
mechanisms of resistance to egfr tyrosine kinase inhibitors | rtcl.tv
-
2:21
treatment of egfr nsclc after progression
-
0:47
mechanisms of resistance to egfr tyrosine kinase inhibitors | rtcl.tv
-
2:01
checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
20:24
targeted treatment with egfr tkis: front line options
-
2:56
non-tki-based treatment options for egfr-mutant lung cancer
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
2:23
the future of tyrosine kinase inhibitors for melanoma and open questions
-
13:06
noemi reguart, esmo 2019 - egfr tyrosine kinase inhibitors in nsclc
-
2:18
prolonging survival in nsclc
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies